Recent advances in head and neck squamous cell carcinoma - A review

Clinical Biochemistry

Volumn 47, Issue 13-14, 2014, Pages 1195-1202

  Safdari, Yaghoub ^a,e   Khalili, Masoumeh ^c   Farajnia, Safar ^b   Asgharzadeh, Mohammad ^d   Yazdani, Yaghoub ^e   Sadeghi, Mahnaz ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e GOLESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Apoptosis; Cetuximab; EGFR; Erlotinib; Head and neck cancer; Radiosensitivity

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANIMAL; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMAN; METABOLISM; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 84929128767     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.05.066     Document Type: Review

References (56)

1. Adelstein D.J., Ridge J.A., Gillison M.L., Chaturvedi A.K., D'Souza G., Gravitt P.E., et al. Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, D.C. Head Neck 2009, 31:1393-1422.
2. Argiris A., Ghebremichael M., Gilbert J., Lee J.W., Sachidanandam K., Kolesar J.M., et al. Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial. J Clin Oncol 2013, 31:1405-1414.
3. Bhattacharya S., Ray R.M., Johnson L.R. STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells. Biochem J 2005, 392:335-344.
4. Brooks H.D., Glisson B.S., Bekele B.N., Johnson F.M., Ginsberg L.E., El-Naggar A., et al. Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 2011, 117:2112-2129.
5. Bussink J., van der Kogel A.J., Kaanders J.H. Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008, 9:288-296.
6. Cassell A., Freilino M.L., Lee J., Barr S., Wang L., Panahandeh M.C., et al. Targeting TORC1/2 enhances sensitivity to EGFR inhibitors in head and neck cancer preclinical models. Neoplasia 2012, 14:1005-1014.
7. Curado M.P., Hashibe M. Recent changes in the epidemiology of head and neck cancer. Curr Opin Oncol 2009, 21:194-200.
8. Day K.E., Sweeny L., Kulbersh B., Zinn K.R., Rosenthal E.L. Preclinical Comparison of Near-Infrared-Labeled Cetuximab and Panitumumab for Optical Imaging of Head and Neck Squamous Cell Carcinoma. Mol Imaging Biol 2013, 15(6):722-729.
9. Flynn A.N., Buret A.G. Caspases-3, -8, and -9 are required for induction of epithelial cell apoptosis by enteropathogenic E. coli but are dispensable for increased paracellular permeability. Microb Pathog 2008, 44:311-319.
10. Gartel A.L., Radhakrishnan S.K. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005, 65(10):3980-3985.
11. Giles K.M., Kalinowski F.C., Candy P.A., Epis M.R., Zhang P.M., Redfern A.D., et al. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib. Mol Cancer Ther 2013, 12(11):2541-2558.
12. Heath C.H., Deep N.L., Beck L.N., Day K.E., Sweeny L., Zinn K.R., et al. Use of panitumumab-IRDye800 to image cutaneous head and neck cancer in mice. Otolaryngol Head Neck Surg 2013, 148:982-990.
13. Iida M., Brand T.M., Campbell D.A., Li C., Wheeler D.L. Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor. Oncogene 2013, 32:759-767.
14. Islam M., Sharma S., Kumar B., Teknos T.N. Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis. Oral Oncol 2013, 49:778-786.
15. Kim S.A., Kim S.W., Chang S., Yoon J.H., Ahn S.G. 5'-nitro-indirubinoxime induces G2/M cell cycle arrest and apoptosis in human KB oral carcinoma cells. Cancer Lett 2009, 274:72-77.
16. Kim S.A., Kwon S.M., Kim J.A., Kang K.W., Yoon J.H., Ahn S.G. 5'-Nitro-indirubinoxime, an indirubin derivative, suppresses metastatic ability of human head and neck cancer cells through the inhibition of Integrin beta1/FAK/Akt signaling. Cancer Lett 2011, 306:197-204.
17. Kinoshita T., Nohata N., Hanazawa T., Kikkawa N., Yamamoto N., Yoshino H., et al. Tumour-suppressive microRNA-29s inhibit cancer cell migration and invasion by targeting laminin-integrin signalling in head and neck squamous cell carcinoma. Br J Cancer 2013, 109:2636-2645.
18. Klausz K., Berger S., van Bueren JJ Lammerts, Derer S., Lohse S., Dechant M., et al. Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Cancer Sci 2011, 102:1761-1768.
19. Klinger B., Sieber A., Fritsche-Guenther R., Witzel F., Berry L., Schumacher D., et al. Network quantification of EGFR signaling unveils potential for targeted combination therapy. Mol Syst Biol 2013, 9:673.
20. Koontongkaew S. The tumor microenvironment contribution to development, growth, invasion and metastasis of head and neck squamous cell carcinomas. J Cancer 2013, 4:66-83.
21. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 2005, 11:1314-1321.
22. Li R., You S., Hu Z., Chen Z.G., Sica G.L., Khuri F.R., et al. Inhibition of STAT3 by niclosamide synergizes with erlotinib against head and neck cancer. PLoS One 2013, 8:e74670.
23. Lin H.Y., Sun M., Tang H.Y., Simone T.M., Wu Y.H., Grandis J.R., et al. Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells. J Cell Biochem 2008, 104:2131-2142.
24. Lin R.J., Lubpairee T., Liu K.Y., Anderson D.W., Durham S., Poh C.F. Cyclin D1 overexpression is associated with poor prognosis in oropharyngeal cancer. J Otolaryngol Head Neck Surg 2013, 42:23.
25. Liu C.J., Shen W.G., Peng S.Y., Cheng H.W., Kao S.Y., Lin S.C., et al. miR-134 induces oncogenicity and metastasis in head and neck carcinoma through targeting WWOX gene. Int J Cancer 2014, 134(4):811-822.
26. Lockhart A.C., Tirona R.G., Kim R.B. Pharmacogenetics of ATP-binding cassette transporters in cancer and chemotherapy. Mol Cancer Ther 2003, 2:685-698.
27. Masui T., Ota I., Kanno M., Yane K., Hosoi H. Low-intensity ultrasound enhances the anticancer activity of cetuximab in human head and neck cancer cells. Exp Ther Med 2013, 5:11-16.
28. Meyn R.E., Munshi A., Haymach J.V., Milas L., Ang K.K. Receptor signaling as a regulatory mechanism of DNA repair. Radiother Oncol 2009, 92:316-322.
29. Ming L.C., Stephenson R., Salazar A.M., Ferris R.L. TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR head and neck cancer cells. Oncoimmunology 2013, 2:e24677.
30. Nottingham L.K., Yan C.H., Yang X., Si H., Coupar J., Bian Y., et al. Aberrant IKKalpha and IKKbeta cooperatively activate NF-kappaB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer. Oncogene 2014, 33(9):1135-1147.
31. Peurala E., Koivunen P., Haapasaari K.M., Bloigu R., Jukkola-Vuorinen A. The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. Breast Cancer Res 2013, 15:R5.
32. Prystowsky M.B., Adomako A., Smith R.V., Kawachi N., McKimpson W., Atadja P., et al. The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines. J Pathol 2009, 218:467-477.
33. Prystowsky M., Feeney K., Kawachi N., Montagna C., Willmott M., Wasson C., et al. Inhibition of Plk1 and Cyclin B1 expression results in panobinostat-induced G(2) delay and mitotic defects. Sci Rep 2013, 3:2640.
34. Prystowsky M.B., Adomako A., Smith R.V., Kawachi N., McKimpson W., Atadja P., et al. The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines. J Pathol 2009, 218:467-477.
35. Pulte D., Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 2010, 15:994-1001.
36. Raju U., Riesterer O., Wang Z.Q., Molkentine D.P., Molkentine J.M., Johnson F.M., et al. Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. Radiother Oncol 2012, 105:241-249.
37. Rao K., Kalapurakal S., Chalasani P., Robinson K., Malone J., Clausen C., et al. A phase II study of intra-arterial cisplatin with concurrent radiation and erlotinib for locally advanced head and neck cancer. Cancer Chemother Pharmacol 2013, 72:545-552.
38. Safdari Y., Farajnia S., Asgharzadeh M., Khalili M., Zarei Jaliani H. Affinity measurement of single chain antibodies: a mathematical method facilitated by statistical software SigmaPlot. Monoclonal Antibodiesin Immunodiagnosis Immunother 2014, 33:13-19.
39. Safdari Y., Farajnia S., Asgharzadeh M., Omidfar K., Khalili M. humMR1, a highly specific humanized single chain antibody for targeting EGFRvIII. Int Immunopharmacol 2014, 18:304-310.
40. Saki M., Toulany M., Rodemann H.P. Acquired resistance to cetuximab is associated with the overexpression of Ras family members and the loss of radiosensitization in head and neck cancer cells. Radiother Oncol 2013, 108:473-478.
41. Sen M., Joyce S., Panahandeh M., Li C., Thomas S.M., Maxwell J., et al. Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res 2012, 18:4986-4996.
42. Sen M., Thomas S.M., Kim S., Yeh J.I., Ferris R.L., Johnson J.T., et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov 2012, 2:694-705.
43. Patel A.N., Mehnert J.M., Kim S. Treatment of Recurrent Metastatic Head and Neck Cancer: Focus on Cetuximab. Clin Med Insights Ear Nose Throat 2012, 5:1-16.
44. Shen Y.A., Lin C.H., Chi W.H., Wang C.Y., Hsieh Y.T., Wei Y.H., et al. Resveratrol Impedes the Stemness, Epithelial-Mesenchymal Transition, and Metabolic Reprogramming of Cancer Stem Cells in Nasopharyngeal Carcinoma through p53 Activation. Evid Based Complement Alternat Med 2013, 2013:590393.
45. Singhi A.D., Westra W.H. Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus-associated head and neck cancer based on a prospective clinical experience. Cancer 2010, 116:2166-2173.
46. Stauber R.H., Knauer S.K., Habtemichael N., Bier C., Unruhe B., Weisheit S., et al. A combination of a ribonucleotide reductase inhibitor and histone deacetylase inhibitors downregulates EGFR and triggers BIM-dependent apoptosis in head and neck cancer. Oncotarget 2012, 3:31-43.
47. Stegeman H., Kaanders J.H., Verheijen M.M., Peeters W.J., Wheeler D.L., Iida M., et al. Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines. Mol Cancer 2013, 12:133.
48. Stegeman H., Span P.N., Rijken P.F., Cockx S.C., Wheeler D.L., Iida M., et al. Dasatinib Inhibits DNA Repair after Radiotherapy Specifically in pSFK-Expressing Tumor Areas in Head and Neck Xenograft Tumors. Transl Oncol 2013, 6:413-419.
49. Stephenson R.M., Lim C.M., Matthews M., Dietsch G., Hershberg R., Ferris R.L. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells. Cancer Immunol Immunother 2013, 62:1347-1357.
50. Way T.D., Huang J.T., Chou C.H., Huang C.H., Yang M.H., Ho C.T. Emodin represses TWIST1-induced epithelial-mesenchymal transitions in head and neck squamous cell carcinoma cells by inhibiting the beta-catenin and Akt pathways. Eur J Cancer 2014, 50(2):366-378.
51. Wheeler S.E. EGFRvIII expression and signaling in head and neck squamous cell carcinoma. The School of Medicine, Department of Pathology 2011, University of Pittsburgh.
52. Wheeler S.E., Morariu E.M., Bednash J.S., Otte C.G., Seethala R.R., Chiosea S.I., et al. Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer. Clin Cancer Res 2012, 18:2850-2860.
53. Wheeler S.E., Suzuki S., Thomas S.M., Sen M., Leeman-Neill R.J., Chiosea S.I., et al. Epidermal growth factor receptor variant III mediates head and neck cancer cell invasion via STAT3 activation. Oncogene 2010, 29:5135-5145.
54. Yang W.H., Lan H.Y., Tai S.K., Yang M.H. Repression of bone morphogenetic protein 4 by let-7i attenuates mesenchymal migration of head and neck cancer cells. Biochem Biophys Res Commun 2013, 433:24-30.
55. Yang Y.P., Chang Y.L., Huang P.I., Chiou G.Y., Tseng L.M., Chiou S.H., et al. Resveratrol suppresses tumorigenicity and enhances radiosensitivity in primary glioblastoma tumor initiating cells by inhibiting the STAT3 axis. J Cell Physiol 2012, 227:976-993.
56. Yu C.C., Tsai L.L., Wang M.L., Yu C.H., Lo W.L., Chang Y.C., et al. miR145 targets the SOX9/ADAM17 axis to inhibit tumor-initiating cells and IL-6-mediated paracrine effects in head and neck cancer. Cancer Res 2013, 73:3425-3440.